natgillin/translations-raw huggingface dataset:
The system according to one of the preceding claims, wherein the auxiliary opening (40c) opens upstream of most radially peripheral stage. 
Sustav sukladno jednom od prethodnih zahtjeva, pri čemu se pomoćni otvor (40c) otvara iznad najviše radijalno periferne faze.
A pharmaceutical composition as specified in claim 16 for the use in the treatment of tumors, wherein the anti-tumor antibody is an anti-EGFR antibody, and said engineered recombinant antibody prevents or delays re-growth of tumor after stop administering the engineered antibody. 
Farmaceutski pripravak kako je navedeno u zahtjevu 16 naznačen time da je za uporabu kod liječenja tumora, pri čemu anti-tumorsko protutijelo je anti-EGFR protutijelo, a navedeno genetički izmijenjeno rekombinantno protutijelo sprečava ili odgađa ponovni rast tumora nakon dovršetka davanja genetički izmijenjenog protutijela.
A combined fireworks with launching pits and multi-channel fireproof structures according to Claim 7, characterized in that a first wiring groove and a second wiring groove are respectively arranged on the top of the first and second fireproof wall of the square-shaped bosses. 
Kombinirani vatromet s lansirnim oknima i višekanalnim vatrootpornim strukturama u skladu s patentnim zahtjevom 6, naznačen time što su prvi utor za ožičenje (19) i drugi utor za ožičenje (20) odgovarajuće smješteni na dnu prve (16) i druge (17) vatrootporne stijenke izbočina kvadratnog oblika.
The hinged outside front wall features some fixing substance along its edges. 
Vanjski prednji preklopni zid uz svoj rub ima tvar za fiksiranje.
An expression vector comprising the nucleic acid molecule according to claim 6. 
Ekspresijski vektor, naznačen time, da sadržava molekulu nukleinske kiseline u skladu s patentnim zahtjevom 6.
Container assembly according to any one of the preceding claims, wherein the separator (31) is a contrast colour, such as blue, to a colour of the tissue. 
Sklop posude prema bilo kojem od prethodnih Zahtjeva, gdje je separator (31) kontrastne boje, poput plave, u odnosu na boju tkiva.
A pharmaceutical composition for administration to the stomach of a patient comprising an effective amount of at least one pharmaceutically acceptable zinc salt in combination with a proton pump inhibitor, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient for use to rapidly increase the pH of the gastric juices in the stomach of a patient in need thereof to at least 3.0 within a period no greater than one hour after administration. 
PATENTNI ZAHTJEVI Farmaceutski pripravak za primjenu u želudac bolesnika, koji sadrži učinkovitu količinu barem jedne farmaceutski prikladne cinkove soli u kombinaciji s inhibitorom protonske pumpe, po izboru u kombinaciji s farmaceutski prikladnim nosačem, aditivom ili pomoćnom tvari za uporabu za brzo povećanje pH želučanih sokova u želucu bolesnika kojemu je to potrebno na barem 3.0 u vremenu ne većem od jednog sata nakon primjene.
The above reactions are conveniently carried out at a temperature in the range, for example, 0 to 150°C, suitably at or near the reflux temperature of the reaction solvent. 
Gornje reakcije se prikladno provode pri temperaturi u rasponu od, na primjer 0 do 150 "C, poželjno pri ili u blizini temperature refluksiranja reakcijskog otapala.
Water, Purified 
5.4 Voda, pročišćena
Package according to anyone of claims 1 to 4, characterised in that the lid comprises an edge wall, the hinge line of the lid being located at the edge wall. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što poklopac ima jednu stijenku brida, pri čemu je linija zakretanja smještena na tu stijenku brida.
The antibody, or binding fragment thereof for use according to Claim 13 or the pharmaceutical composition for use according to Claim 13, wherein said malignant tumor is selected from the group consisting of: melanoma, non-small cell lung cancer, hepatocellular carcinoma, gastric cancer, bladder cancer, lung cancer, renal cell carcinoma, cervical cancer, colon cancer, colorectal cancer, head and neck cancer, breast cancer, oesophageal cancer, bone cancer, prostate cancer, basal cell carcinoma, biliary tract cancer, brain and CNS cancer, choriocarcinoma, connective tissue cancer, cancer of the digestive system, endometrial cancer, eye cancer, intra-epithelial cancer, kidney cancer, larynx cancer, leukaemia, liver cancer, lymphoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, rhabdomyosarcoma, sarcoma, skin cancer, testicular cancer, thyroid cancer, uterine cancer, urinary tract cancer, and pancreatic cancer. 
Protutijelo ili njegov fragment za vezanje, za uporabu u skladu s patentnim zahtjevom 10, ili farmaceutski pripravak za uporabu u skladu s patentnim zahtjevom 10, naznačen/o time, da je navedeni maligni tumor odabran iz skupine koja se sastoji od sljedećih: melanom, rak ne-malih stanica pluća, hepatocelularni karcinom, rak želuca, rak mokraćnog mjehura, rak pluća, karcinom renalnih stanica, rak cerviksa, rak debelog crijeva, kolorektalni rak, rak glave i vrata, rak dojke, rak jednjaka, rak kostiju, rak prostate, karcinom bazalnih stanica, rak žučnog trakta, rak mozga i centralnog nervnog sustava, koriokarcinom, rak vezivnog tkiva, rak digestivnog trakta, endometrijski rak, rak oka, intraepitelni rak, rak bubrega, rak grla, leukemija, rak jetre, limfom, mijelom, neuroblastom, rak oralne šupljine, rak jajnika, rabdomiosarkom, sarkom, rak kože, rak testisa, rak tiroidne žlijezde, rak maternice, rak urinarnog trakta i rak gušterače.
wherein: the scan index of the last significant coefficient is determined based on the x index and the y index, 
dekodiranje zadnjeg značajnog koeficijenta transformacije na osnovu lokacije zadnjeg značajnog koeficijenta transformacije;
C—at least one pH-active agent selected from the group, consisting of acid compounds or selected from the group, consisting of hydroxide compounds. The stripping composition of claim 1, wherein B—the at least one high-boiling co-solvent is selected from the group, consisting of high-boiling glycols and glycol ethers, wherein the high-boiling co-solvent has a boiling point of at least 100° C.; and 
Sastav za skidanje u skladu sa zahtjevom 1, naznačen time da B- najmanje jedno suotapalo visokog vrelišta odabrano je iz skupine, koja se sastoji od glikola visokog vrelišta i glikol etera, pri čemu suotapalo s visokim vrelištem ima vrelište od najmanje 100°C; i C- najmanje jedno pH aktivno sredstvo odabrano iz skupine, koja se sastoji od kiselinskih spojeva.
An object of the present invention therefore relates to a stereoregular diblock polybutadiene composed of a polybutadiene block with a 1,4-cis structure and a polybutadiene block with a syndiotactic 1,2 structure, having the following formula (I): 
HR P20190874 T1 PATENTNI ZAHTJEVI Stereoregularni diblok polibutadien, naznačen time što se sastoji od polibutadienskog bloka koji ima 1,4-cis strukturu i polibutadienskog bloka koji ima 1,2 sindiotaktičku strukturu sljedeće formule (I):
Next, Formula 35 was coupled with a sidechain of Formula 36 to form Formula 37 according to the following reaction: Here, the sidechain of Formula 36, (38g, 99.6 mmol) was dissolved in toluene to a known concentration (0.09524 g/mL). 
Forma 35 Formula a7 Ovdje je bočni lanac formule 36 (38 g, 99.6 mmol) bio otopljen u toluenu do poznate koncentracije (0.09524 g/mL).
The compound of paragraph 10 wherein X is selected from optionally substituted 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl. 
Spoj prema zahtjevu 7, naznačen time da je X opcionalno supstituirani 1,2,3-triazinil, 1,2,4-triazinil, 1,3,5-triazinil, piridinil, pirazinil, piridazinil ili pirimidinil.
the pharmaceutical composition of claim 8; instructions for use thereof; and, optionally, 
C) instrukcije za uporabu istog; te, opcionalno, d) o adjuvans.
The process according to claim 1 wherein said compound of formula III is present in an amount varying from about 0.5 to about 50 moles per mole of compound of formula (II). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj formule III dolazi u rasponu količina od otprilike 0,5 do otprilike 50 mol/mol spoja formule II.
The method of claim 1, wherein the composition is in a form adapted for oral administration. 
Sastav za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se sastav prilagođava za oralnu primjenu.
wherein is a bicyclic ring system which contains 9 to 11 ring members including 1 to 4 hetero atoms, in which said bicyclic ring system may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, —C(O)Ra, —SO2Ra, arylalkyl, —(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, 
R, je biciklički sustav prstena koji sadrži 9 do 11 članova u prstenu, uključujući 1 do 4 heteroatoma,, koje se neovisno bira iz skupine koju čine N, O, te S, gdje navedeni biciklički sustav prstena može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C,-Cy4alkil, supstituirani Cy-Cgalkil, C3-C;cikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R,, arilalkil, (C,-Csalkil)ariloksi, aril, heteroaril i C,-C,alkoksi, gdje je svaki R, neovisno C,-Csalkil, supstituirani C;-Csalkil ili nesupstituirani C3-Crcikloalkil; svaki R> i Rs je neovisno vodik, C,-Cgalkil, supstituirani C,-Csalkil, halogen, hidroksil, amid, karboksilna kiselina ili C,-Cualkoksi; i m je 0-2; ili njegova farmaceutski prihvatljiva sol.
Example 12: Clinical effects on awakening and vigilance 
Primjer 13: Klinički učinci na budnost i pažnju
A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav prema zahtjevu 21, koji nadalje sadrži farmaceutski prihvatljiv nosač.
The mixture was poured into a saturated aqueous solution of ammonium chloride (7500 ml) and extracted with ethyl acetate. 
Smjesu se izlije u zasićenu vodenu otopinu amonijevog klorida (7500 ml), te ekstrahira etilacetatom.
9 shows the discharge device 1 in the discharge state in the intermediate position. 
Slika 9 pokazuje napravu za pražnjenje 1 u stanju za pražnjenje u međupoložaju.
The method of claim 1, further comprising fusion-registration of (a) the at least one irradiated readout image with, (b) the at least one control readout image. 
Postupak prema patentom zahtjevu 1, naznačen time što nadalje sadrži usporedbu najmanje jedne slike očitavanja s najmanje jednom trodimenzionalnom raspodjelom doze koja je izračunata pomoću sustava za planiranje radioterapijskog liječenja.
The method according to one or more of the preceding claims 15 to 27, comprising providing a machine for producing therapeutic hosiery items that is a circular hosiery knitting machine with multiple feeds, said first rows of knitting (1) being formed at feeds or drops that are alternated, in the arrangement of the feeds or drops around the axis of the needle cylinder, with feeds or drops that are used to form said second rows of knitting (2). 
Postupak prema jednom ili više prethodnih zahtjeva 15 do 27, naznačen time, da on uključuje predviđanje stroja za izradu terapeutskih čarapa i to kružnog stroja za pletenje čarapa s više dovodnih naprava, pri se čemu neparni redovi pletiva (1) izrađuju na dovodnim napravama, odnosno transporterima koji su raspoređeni naizmjenično oko osi cilindra s iglama, s dovodnim napravama, odnosno transporterima koji se koriste za izradu spomenutih parnih redova pletiva (2).
The rapidly stirred solution was treated by portionwise addition of solid potassium carbonate in order to attain pH -8.5. 
Brzo miješanu otopinu obrađuje se dodavanjem čvrstog kalijevog karbonata u obrocima kako bi se postiglo pH 8,5.
inserting nucleic acids encoding for one or more of the following N-glycosylated optimized amino acid consensus sequence(s): EPMATHMARKEREP wherein X and Z may be any natural amino acid except Pro, into said nucleic acids of a), 
Uporaba jedne ili više sekvenci aminokiselina koje sadrže sekvencu D/E- X- N-Z-S/T, gdje X i Z mogu biti bilo koja prirodna aminokiselina osim prolina, za modificiranje proteina tako da oligosaharil transferaza iz Campylobacter spp. može taj protein N-glikozilirati.
For example, Streit et. al. structurally identified several rapamycin metabolites from human liver microsomes. 
Na primjer, Streit i sur. strukturno su identificirali nekoliko rapamicinskih metabolita iz mikrosoma ljudske jetre.
heating the solution resulting from step (vi) to a temperature of 50 to 100°C for 0.15 to 30 minutes; 
(vli)zagrijavanje otopine dobivene u koraku (vi) do temperature od 50 do 100%C kroz 0.15 do 30 minuta;
The method of any one of claims 1 to 4, wherein the end marker is set in a header of the special data packet to indicate the end of sending the user data packets. 
pri čemu je završna oznaka postavljena u zaglavlje posebnog paketa podataka da se naznači kraj slanja paketa korisničkih podataka.
Use of an effective amount of an anti-CD40 monoclonal antibody according to any of claims 1-10 in the manufacture of a medicament for inhibiting a CD40 ligand-mediated CD40 signaling pathway in a human CD40-expressing cell. 
. Upotreba učinkovite količine anti-CD40 monoklonalnog antitijela prema bilo kojem zahtjevu od 1 do 10 u proizvodnji lijeka za inhibiciju CD40 ligandom-posredovanog CD40 signalnog puta kod humane CD40- ekspresijske stanice, t>
introducing in said neural stem cell an expression vector encoding the CB1 cannabinoid receptor to increase the expression of the CB1 cannabinoid receptor above basal levels, and/or 
(ii) uvođenje u navedenu neuralnu matičnu stanicu ekspresijskog vektora koji kodira kanabinoidni receptor CB, kako bi se povećalo eksprimiranje kanabinoidnog receptora CB; iznad osnovne razine, i/ili
energizing said motor assembly (22, 24) for rotating said mixing element (60) in said first direction (A), 
pogonjenja navedenog motorskog sklopa (22, 24) radi vrtnje navedenog elementa za miješanje (60) u navedenom prvom smjeru (A), -
Use of a compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of allergic diseases and other inflammatory conditions. 
Upotreba spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 12, ili njegove farmaceutski prihvatljive soli, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje alergijskih bolesti i drugih upalnih stanja.
The system according to claim 6, wherein the e-wallet of the user is accessible to the gaming machine for a limited time period. 
Sustav za igranje sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu je račun korisnikovog e-novčanika (71) dostupan uređaju za igru tijekom ograničenog vremenskog perioda.
converting the compound of Formula XXIV to a compound of Formula XXV; and 
Formula XXIV d. konverziju spoja Formule XXIV u spoj Formule XXV: a
A process according to claim 1 or 2, characterized in that R represents methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, phenethyl, tetrahydropyranyl or -C(=O)-CH3. 
Postupak prema zahtjevu 1, naznačen time da R predstavlja metil, etil, n-propil, izopropil, n-butil, izobutil, terc- butil, n-pentil, ciklopropil, ciklobutil, ciklopentil, cikloheksil, cikloheptil, benzil, fenetil, tetrahidropiranil,
Method according to any one of claims 1 to 4, characterised in that the AB-aggregates have been prepared by incubating AB-1-42 peptides, AB-1-43 peptides, AB-3-42, or AB-p(E)3-42 peptides at a pH of 2 to 9 for at least 20 min, preferably at least 1 h, especially at least 4 h. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se AGB-agregati pripravljaju pomoću inkubacije AB-1-42-peptida, AB-1-43-peptida, AB-3-42-peptida ili AG-p(E)3-42-peptida, s pH vrijednosti od 2 do 9, u vremenu od najmanje 20 min, poželjno najmanje od 1 sata, posebno pogodno od najmanje 4 sata.
The method according to claim 11, wherein the composition is administered to a subject to provide a dosage of 1-5000 ug/kg of MK-467 and 0.1-20000 ug/kg of the a2-adrenoceptor agonist. 
MK-467 za medicinsku upotrebu kod pacijenta kojem je potrebna sedacija prema bilo kojem patentnom zahtjevu 11-13, naznačen time da se pripravak daje pacijentu u dozi od 1-5000 ug/kg MK-467 i 0.1 do 2000 ug/kg agonista a2- adrenoceptora.
The solvent is evaporated off and the residue is freeze-dried, to obtain hydrochloride (1') as yellow solid. 
Otapalo je upareno a ostatak je liofilizlran i dobiven je hldroklorid (1') kao žuta krutina.
In the first trial, the rats are exposed to two identical objects in an open field. 
U prvom pokusu, štakorima su prikazana dva jednaka predmeta u otvorenom području.
wherein a size of the transformation unit split from the coding unit is determined independently from a size of the at least one prediction unit in the coding unit, 
određivanje barem jedne transformacijske jedinice koja je razdvojena iz jedinice kodiranja koristeći informaciju o transformacijskoj jedinici, pri čemu je informacija o transformacijskoj jedinici raščlanjena iz toka bitova;
An adhesive composition according to claim 3, wherein the chain-extending reagent (ii) is a polyether polyol selected from ethoxylated and propoxylated derivatives of tri- or higher functional polyols, and optionally wherein the chain-extending reagent (ii) is a polyether polyol selected from ethoxylated and propoxylated derivatives of trimethylol propane and ethoxylated and propoxylated derivatives of pentaerythritol. 
Sastav ljepila prema zahtjevu 5, naznačen time, da reagens produljivanja lanca (ii) je polieter-poliol odabran od etoksiliranih i propoksiliranih derivata od trostruko ili višefunkcionalnih poliola, poželjno trofunkcionalnih ili tetrafunkcionalnih poliola.
In table 2, R1 is an unsubstituted pyridin-4-yl group, or, an unsubstituted pyrimidin-4-yl group, p, m represent 2, o represents 1 and q represents 0. 
HR P20070328 T3 U Tablici 2: R1 je nesupstituirana piridin-4-ilna skupina ili nesupstituirana pirimidin-4-ilna skupina, p i m znače 2, o znači 1, a q znači 0.
Reference compound C 
Referentni spoj C
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, W is CRw or N, wherein Rw is selected from the group consisting of 
Na Hi ili njegov stereoizomer, tautomer ili farmaceutski prihvatljiva sol, gdje W je CRy ili N, gdje je Ry odabran iz skupine koja sadrži
evaluating, on the part of the subscriber server, whether to perform step c) or not depending on the authorization reply. 
procjena (350), od strane navedenog pretplatničkog servera (150), da li da se izvede korak c) ili ne u odnosu od navedenog odgovora na autorizaciju.
(wherein, Ring A represents a benzene ring or a thiophene ring, 
14] (gdje, Prsten A predstavlja benzen-prsten ili tiofen-prsten,
The antisense oligonucleotide or pharmaceutically acceptable salt thereof according to claim 1, wherein the intersubunit linkage joining two adjacent morpholino subunits has the following structure: wherein: 
Protusmisleni oligonukleotid ili njegova farmaceutski prihvatljiva sol prema zahtjevima 1-4, naznačen time što je oligonukleotid konjugiran na lanac polietilen glikola.
A combined fireworks with launching pits and multi-channel fireproof structures according to Claim 4, characterized in that the fireproof bosses are circular bosses, and a recessed countersink is arranged in the exact center of the circular bosses within which provided with priming holes for mounting leads. 
Kombinirani vatromet s lansirnim oknima i višekanalnim vatrootpornim strukturama u skladu s patentnim zahtjevom 3, naznačen time što su vatrootporne izbočine kružne izbočine (10), a izdubljena udubina (11) je smještena u točnom središtu kružnih izbočina u kojima imaju upaljačke rupe (8, 9) za ugradnju vodova.
A type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC) for use in the treatment of a patient suffering from a CD20 expressing cancer in combination with one ore more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine, characterized in that said type II anti-CD20 antibody is a glycoengineered, humanized B-Ly1 antibody, wherein the humanized B-Ly1 antibody has variable region of the heavy chain (VH) of SEQ ID No.7 and a variable region of the light chain (VL) of SEQ ID No. 20, and the treatment with the type II anti-CD20 antibody is in combination 
Protutijelo anti-CD20 tipa II s povećanom ovisnošću stanične citotoksičnosti o protutijelu (ADCC), za uporabu u liječenju pacijenta koji boluje od raka koji izražava CD20, u kombinaciji s jednim ili više kemoterapeutskih sredstava odabranih iz skupine koju čine ciklofosfamid, vinkristin i doksorubicin, naznačeno time, da navedeno protutijelo anti-CD20 je pomoću glikoinženjeringa modificirano, humanizirano protutijelo B-Ly1, pri čemu to humanizirano protutijelo B-Ly1 ima varijabilno područje jakog lanca (VH) od SEQ ID NO:7 i varijabilno područje slabog lanca (VL) od SEQ ID NO:20, dok je liječenje s protutijelom anti- CD20 tipa II u kombinaciji sa sljedećima: c)
an outlet (10) for thermal oil 
- izlaz (10) za toplinsko ulje
The dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition. 
Brzina otapanja kompaktne čvrste farmaceutske smjese u želucu pacijenta se može povećati dodavanjem sredstva za raspadanje u smjesu.
The compounds of formula I of the invention can be prepared as shown in the following reaction schemes and description thereof, as well as relevant published literature procedures that may be used by one skilled in the art. 
Spojevi formule I iz izuma mogu se pripremiti kao što je prikazano u slijedećim reakcijskim prikazima i njihovim opisima, jednako kao i postupcima u odgovarajućoj objavljenoj literaturi koje mogu upotrijebiti osobe iz struke.
Use of a polypeptide dimer as defined in any one of claims 1 to 11 for the preparation of a pharmaceutical composition for the treatment and/or prevention of bone resorption, hypercalcemia, cachexia, a tumor or other type of cancer, an autoimmune disease, an inflammatory or atopic disease, an infection, an endocrinologic disorder or a metabolic or catabolic disease. 
Uporaba polipeptidnog dimera kao što je definiran u bilo kojem od patentnih zahtjeva 1 do 11 za pripremu farmaceutskih smjesa za liječenje i/ili prevenciju resorpcije kostiju, hiperkalcemije, kaheksije, tumora ili druge vrste raka, autoimune bolesti, upalne ili atopične bolesti, infekcije, endokrinološkog poremećaja ili metaboličke ili kataboličke bolesti. t>& HR P20100663 T1 4 JUEJNUIJ
is a 6-membered heteroaryl ring containing two nitrogen members substituted with one or more members selected from the group consisting of: halo, C1-4alkyl, CD3, D, C1-4alkoxy, cyclopropyl, morpholin-2-yl, CO2C1-4alkyl, CO2H, CH2OH, C(O)N(C1-4alkyl)2, CF3, CN, OH, NO2, N(C1-4alkyl)2, phenyl, furan-2-yl, thiophen-2-yl, 1H-pyrazol-4-yl, and pyrrolidin-1-yl; or a pharmaceutically acceptable salt of a compound of Formula (I), and at least one pharmaceutically acceptable excipient for use in a method of treating a subject suffering from or diagnosed with a disease, disorder, or medical condition mediated by orexin receptor activity. 
je 6-člani heteroarilni prsten koji sadrži dva atoma dušika supstituirana sa jednim ili više članova izabranih iz grupe koju čine: halo, C1-4alkil, CD3, D, C1-4alkoksi, ciklopropil, morfolin-2-il, CO2C1-4alkil, CO2H, CH2OH, C(O)N(C1-4alkil)2, CF3, CN, OH, NO2, N(C1-4alkil)2, fenil, furan-2-il, tiofen2-il, 1H-pirazol-4-il, i pirolidin-1-il; ili farmaceutski prihvatljiva sol spoja formule (I), i barem jednu farmaceutski prihvatljivu pomoćnu tvar za upotrebu u postupku liječenja subjekta koji pati od ili kod kojeg je dijagnosticirana bolest, poremećaj ili medicinsko stanje posredovano aktivnošću receptora oreksina.
Medical uses of the compositions of the invention 
Datum objave europske prijave patenta: